|Bid||283.35 x 100|
|Ask||287.05 x 100|
|Day's Range||285.03 - 296.80|
|52 Week Range||244.28 - 333.65|
|PE Ratio (TTM)||18.04|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 2Q17, Biogen’s (BIIB) Spinraza generated revenue of ~$203 million, compared to $47 million in 1Q17.
In 2Q17, Biogen’s (BIIB) Tecfidera generated revenue of ~$1.1 billion, which reflected a ~13% rise year-over-year (or YoY) and a ~16% rise quarter-over-quarter.
In 2Q17, Biogen’s (BIIB) net revenue from the sale of interferons amounted to ~$691 million, a 5% fall year-over-year (or YoY) and a ~7% rise quarter-over-quarter.